secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001193125-24-073324
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine reports FY2023 net loss $76.4M, cash $360.4M; AURORA topline data expected March/April 2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $360.4M at Dec 31, 2023, providing runway well into 2026.
- Net loss of $76.4M for FY2023 vs $46.8M in 2022, driven by higher R&D costs ($69.3M vs $33.4M).
- Topline results from AURORA phase 2 study of bitopertin in EPP expected March/April 2024.
- Updated phase 1b/2 data for DISC-0974 in anemia of myelofibrosis expected 1H 2024.
- Appointed Jean Franchi as CFO, Pamela Stephenson as CCO, promoted Jonathan Yu to COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/0001193125-24-073324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/d795577d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-073324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer